Tianli International Holdings (01773) received 50,000 shares additional purchase by executive director Luo Shi.
Tianli International Holdings (01773) announced that the Board of Directors has been notified by Mr. Luo Shi, the Executive Director, Chairman, and Chief Executive Officer of the company, that on January 16, 2026, he purchased a total of 500,000 ordinary shares of the company in the open market, representing approximately 0.02% of the total issued share capital of the company, at an average price of approximately HKD 2.81 per share.
TIANLI INT HLDG (01773) announces that the Board of Directors has been informed by the Executive Director, Chairman and CEO of the company, Mr. Luo Shi, that on January 16, 2026, Mr. Luo Shi purchased a total of 500,000 shares of the company's common stock in the open market, representing approximately 0.02% of the total number of issued shares of the company, at an average price of approximately HK$2.81 per share. Following the purchase, Mr. Luo Shi directly and indirectly holds a total of 920 million shares of the company, representing approximately 43.94% of the total number of issued shares of the company as of the date of this announcement (excluding 13.227 million shares repurchased on or before the date of this announcement but not yet canceled and 2.2 million shares held in treasury). Mr. Luo Shi has also been granted 30 million share options under the share option plan, entitling him to subscribe for 30 million shares, which are currently unexercised.
Mr. Luo Shi has expressed confidence in the business prospects and outlook of the Group. Subject to applicable legal and regulatory requirements, Mr. Luo Shi does not rule out the possibility of further increasing his shareholding in the company at the appropriate time.
In addition, on January 16, 2026, the company repurchased 200,000 shares of its own stock in the open market, representing approximately 0.0095% of the total number of issued shares of the company. These repurchased shares will be held by the company as treasury shares.
Related Articles

Haisco Pharmaceutical Group (002653.SZ): Innovative drug HSK31679 tablet included in breakthrough therapy program.

Yinbang Clad Material (300337.SZ) is planning to register and issue medium-term notes.

HK Stock Market Move | NATURAL FOOD IH(01837) continues to rise by over 5%, offline channel business significantly grows, with annual net profit increasing by approximately 40% compared to the previous year.
Haisco Pharmaceutical Group (002653.SZ): Innovative drug HSK31679 tablet included in breakthrough therapy program.

Yinbang Clad Material (300337.SZ) is planning to register and issue medium-term notes.

HK Stock Market Move | NATURAL FOOD IH(01837) continues to rise by over 5%, offline channel business significantly grows, with annual net profit increasing by approximately 40% compared to the previous year.

RECOMMEND

“A+H” Team Continues To Expand Hard Technology Firms Accelerate Global Deployment
11/03/2026

Anti‑Stagflation Theme Guides Hong Kong Allocation Institutions Identify Power And Energy Assets As Short‑Term Core
11/03/2026

U.S. Equities Enter “Always‑On” Trading Era Nasdaq Advances Stock Tokenization Framework
11/03/2026


